IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-170X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma ; volume:28 ; number:12 ; day:16 ; month:12 ; year:2022 ; pages:2592-2600 ; date:12.2022
Nature medicine ; 28, Heft 12 (16.12.2022), 2592-2600, 12.2022
- Urheber
-
Taylor, Chelsea A.
Watson, Robert A.
Tong, Orion
Ye, Weiyu
Nassiri, Isar
Gilchrist, James J.
los Aires, Alba Verge de
Sharma, Piyush Kumar
Koturan, Surya
Cooper, Rosalin A.
Woodcock, Victoria K.
Jungkurth, Elsita
Shine, Brian
Coupe, Nicholas
Payne, Miranda J.
Church, David N.
Naranbhai, Vivek
Groha, Stefan
Emery, Paul
Mankia, Kulveer
Freedman, Matthew L.
Choueiri, Toni K.
Middleton, Mark R.
Gusev, Alexander
Fairfax, Benjamin P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-022-02095-5
- URN
-
urn:nbn:de:101:1-2023031021123364039550
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Taylor, Chelsea A.
- Watson, Robert A.
- Tong, Orion
- Ye, Weiyu
- Nassiri, Isar
- Gilchrist, James J.
- los Aires, Alba Verge de
- Sharma, Piyush Kumar
- Koturan, Surya
- Cooper, Rosalin A.
- Woodcock, Victoria K.
- Jungkurth, Elsita
- Shine, Brian
- Coupe, Nicholas
- Payne, Miranda J.
- Church, David N.
- Naranbhai, Vivek
- Groha, Stefan
- Emery, Paul
- Mankia, Kulveer
- Freedman, Matthew L.
- Choueiri, Toni K.
- Middleton, Mark R.
- Gusev, Alexander
- Fairfax, Benjamin P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Predictors of responses to immune checkpoint blockade in advanced melanoma
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Predictors of responses to immune checkpoint blockade in advanced melanoma
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Predictors of responses to immune checkpoint blockade in advanced melanoma
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade